Saturday, June 5, 2004

ASCO 2004 ASCO 2004
For those users interested in obtaining CME for this program, please enter the CME portion of this course. To receive CME for each day, you must view all reports and fax the required documentation at the conclusion of the reviews.

In order to print the required documentation, you will need Adobe Reader, which is available for free on the Adobe Website.

OncoLink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.


ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma.  Final results of the IIL HD9601 randomized trial
Association between androgen deprivation therapy and fracture risk:  A population-based cohort study in men with non-metastatic prostate cancer.
Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911)
Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial
MRI detection of multi focal breast carcinoma:  Report from the International Breast MRI Consortium
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer
What we learned on June 5, 2004